- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03578796
Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen in Noorwegen: een prospectieve cohortstudie
Cognitieve stoornissen bij ALS: screeningtools, ervaringen en prognose
This study evaluate use of a translated Norwegian version of the Edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen (ECAS-N) as an early predictor in car-driving, working and use of advanced life-prolonging therapy.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Cognitive impairment is present in about 30-50% of the patients with amyotrophic lateral sclerosis (ALS). Screening of cognitive and behavioral impairment is a distinct recommendation in ALS-specific health care. However, knowledge in how cognitive impairment shall influence health-care professionals' information given to patients and in decision making is lacking.
One of the major challenges in ALS management is the decision-making on advanced therapy. There is a lack of knowledge in how cognitive impairment in ALS shall be interfere on complex medical treatment that will affect quality of life or life itself. This means significant implications not only to the ALS patient and the community, but also the family and especially the spouse. Thus, further investigation of the ECAS-N and its potential in clinical use is needed. The scale may contribute a more proactive treatment better tailored to individual needs. The objective is to evaluate if the ECAS-N can be applied as an early predictor in car-driving, working and use of advanced life-prolonging therapy
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Norway
-
Bergen, Norway, Noorwegen, 5021
- Haukeland University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Patients who fullfill the inclusion criteria and attending to the ALS-clinic at HUH within 4 months after being diagnosed with ALS.
Beschrijving
Inclusion Criteria:
- Voluntary informed consent
- Native Norwegian speaker
Exclusion Criteria:
- Great difficulties in writing or reading
- Comorbid medical history
- Neurological disorders others than ALS
- Psychiatric history of importance to cognitive function
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Persons with ALS
Persons With possible ALS-specific cognitive impairment will be tested With ECAS-N, MoCA, CDR and a questionnaire at 4 months (baseline) and 8 months (1. follow-up). Further evaluation will be with the questionnaire and CDR at each follow-up until 3 years or use of permanent ventilation support or Death. Information about use of advanced life-prolonging therapy will be collected from patient journal. |
assessing ALS-specific cognitive impairment
Andere namen:
assessing cognitive impairment
Andere namen:
assessing global cognitive impairment, as well as possible diagnosis- and Level of dementia
Andere namen:
Questions related to work situation and car driving |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Clinical Dementia Rating (CDR)
Tijdsspanne: 8 months
|
We will use the total CDR score (minimum score = 0, maximum score = 18). Low scores indicate less problems than high scores. |
8 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Clinical Dementia Rating (CDR)
Tijdsspanne: 4 months
|
We will use the total CDR score (minimum score = 0, maximum score = 18). Low scores indicate less problems than high scores. |
4 months
|
|
Clinical Dementia Rating (CDR)
Tijdsspanne: 3 years or until death
|
We will use the total CDR score (minimum score = 0, maximum score = 18). Low scores indicate less problems than high scores. |
3 years or until death
|
|
Ability in car-driving
Tijdsspanne: 8 months
|
We will use a categorical variable (yes or no) and time of change to reduced function. |
8 months
|
|
Ability in car-driving
Tijdsspanne: 4 months
|
We will use a categorical variable (yes or no) and time of change to reduced function. |
4 months
|
|
Ability in car-driving
Tijdsspanne: 3 years or until death
|
We will use a categorical variable (yes or no) and time of change to reduced function. |
3 years or until death
|
|
Working ability
Tijdsspanne: 8 months
|
We will use a categorical variable (yes or no) and time of change to reduced function. |
8 months
|
|
Working ability
Tijdsspanne: 4 months
|
We will use a categorical variable (yes or no) and time of change to reduced function. |
4 months
|
|
Working ability
Tijdsspanne: 3 years or until death
|
We will use a categorical variable (yes or no) and time of change to reduced function. |
3 years or until death
|
|
Use of Advanced life-prolonging therapy
Tijdsspanne: 8 months
|
We will use a categorical variable (yes or no) and time of change to reduced function. |
8 months
|
|
Use of Advanced life-prolonging therapy
Tijdsspanne: 4 months
|
We will use a categorical variable (yes or no) and time of change to reduced function. |
4 months
|
|
Use of Advanced life-prolonging therapy
Tijdsspanne: 3 years or until death
|
We will use a categorical variable (yes or no) and time of change to reduced function. |
3 years or until death
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen-Norwegian Version (ECAS-N)
Tijdsspanne: 4 months
|
We will use the ALS-specific sub-score (minimum score = 0, maximum score = 100), the ALS non-specific sub-score (minimum score = 0, maximum score = 36), a summed total ECAS-N score (minimum score =0, maximum score =136), the sub score of behavioural changes (minimum score = 0, maximum score = 10) and the sub score of psychotic change (minimum score = 0, maximum score = 3). A dichotomized cut-off scores for normality will also be used for the ALS-specific cut-off score of 65 or over, the non ALS-specific cut-off score of 24 or over and the total ECAS-N cut-off score of 92 or over. For the ALS-specific scores, non ALS-specific scores and total ECAS-N scores, high scores indicate less problems than low scores. For the sub score of behavioural change and the sub score of psychotic change, high scores indicate more problems than low scores. |
4 months
|
|
Change from 4 months Edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen-Norwegian Version (ECAS-N) at 8 months
Tijdsspanne: 8 months
|
We will use the changed ALS-specific sub-score (minimum score = 0, maximum score = 100), the changed ALS non-specific sub-score (minimum score = 0, maximum score = 36), a changed summed total ECAS-N score (minimum score =0, maximum score =136), the changed sub score of behavioural changes (minimum score = 0, maximum score = 10) and the changed sub score of psychotic change (minimum score = 0, maximum score = 3). A changed dichotomized cut-off scores for normality will also be used for the ALS-specific cut-off score of 65 or over, the non ALS-specific cut-off score of 24 or over and the total ECAS-N cut-off score of 92 or over. For the ALS-specific scores, non ALS-specific scores and total ECAS-N scores, high scores indicate less problems than low scores. For the sub score of behavioural change and the sub score of psychotic change, high scores indicate more problems than low scores. |
8 months
|
|
Montreal Cognitive Assessment (MoCA)
Tijdsspanne: 4 months
|
We will use the total MoCA score (minimum score = 0, maximum score = 30) and a dichotomized cut-off score for normality of 26 or over. High scores indicate less problems than low scores |
4 months
|
|
Change from 4 months Montreal Cognitive Assessment (MoCA) at 8 months
Tijdsspanne: 8 months
|
We will use the changed total MoCA score (minimum score = 0, maximum score = 30) and the changed dichotomized cut-off score for normality of 26 or over. High scores indicate less problems than low scores |
8 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Tina Taule, PhD, Haukeland University Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Neuromusculaire aandoeningen
- Metabole ziekten
- Neurocognitieve stoornissen
- Cognitieve stoornissen
- Neurodegeneratieve ziekten
- Ziekten van het ruggenmerg
- TDP-43 Proteïnopathieën
- Proteostase-tekortkomingen
- Motor Neuron Ziekte
- Voedings- en stofwisselingsziekten
- Cognitieve disfunctie
- Amyotrofische laterale sclerose
- Kwaliteit, toegang en evaluatie van de gezondheidszorg
- Onderzoekstechnieken
- Epidemiologische methoden
- Gegevensverzameling
- Evaluatiemechanismen voor gezondheidszorg
- Kwaliteit van de gezondheidszorg
- Volksgezondheid
- Milieu en volksgezondheid
- Enquêtes en vragenlijsten
Andere studie-ID-nummers
- 2016/2187-1
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .